Randomized clinical trial: a controlled pilot trial of the 5‐HT₄ receptor agonist revexepride in patients with symptoms suggestive of gastroparesis

Abstract

Four weeks of revexepride treatment did not improve symptoms or gastric emptying over placebo in patients with symptoms suggestive of gastroparesis.

The American neurogastroenterology and motility society gastroparesis cardinal symptom index‐daily diary (ANMS GCSI‐DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis

“…A symptom questionnaire-the Gastroparesis Cardinal Symptom Index (GCSI)-originally developed through patient interviews, was validated in university-based clinical practices for assessing symptoms in gastroparesis. 5,6 The GCSI has a two-week recall and is the most frequently used symptom severity measure in gastroparesis clinical trials and other clinical studies, [7][8][9][10][11][12][13][14][15][16][17][18][19] including the National…”

Chronic Unexplained Nausea and Vomiting or Gastric Neuromuscular Dysfunction (GND)? An Update on Nomenclature, Pathophysiology and Treatment, and Relationship to Gastroparesis

“…27 Unfortunately, the drug had no significant effect on symptoms when compared with placebo. This is not surprising considering that many patients may have had normal emptying to begin with, along with the now well-established lack of correlation between a prokinetic effect and improved symptoms.…”

The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review

“…Several 5-HT receptor agonists/antagonists, such as cisapride (5-HT4 agonist, 5-HT2, and 5-HT3 antagonist), tegaserod (5-HT4 and 5-HT1 agonist, 5-HT2a/b antagonist), mosapride (5-HT4 agonist, 5-HT3 antagonist) and revexepride (5-HT4 agonist) have been evaluated for the treatment of dyspepsia and gastroparesis, although not all studies show efficacy (114)(115)(116). A recent metanalysis showed that FD patients treated with serotonin receptor agonists have a significantly better symptom response compared to placebo (117) and the most recently published evidence indicates efficacy for prucalopride in idiopathic gastroparesis and emerging efficacy for velusetrag in gastroparesis (118,119).…”